SCHEMBL25933737

SCHEMBL25933737

COC(=O)c1cnc(C2CC3(CC(C)C3)C2)c(F)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.35
ATM Q13315 1/20 0.35
MGLL Q99685 1/20 0.35
POLB P06746 2/20 0.34
KDM4E B2RXH2 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
PSMD14 O00487 1/20 0.34
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
LMNA P02545 1/20 0.33
GAA P10253 1/20 0.33
NFKB1 P19838 1/20 0.33
XDH P47989 1/20 0.33
GFER P55789 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25333591 0.90 MAPK1 (0.35) MAPK1ATMMGLLPOLBKDM4E
SCHEMBL25331869 0.86 MGLL (0.36) MAPK1ATMMGLLPOLBKDM4E
SCHEMBL30516582 0.86 MAPK1 (0.38) MAPK1ATMPOLBKDM4EL3MBTL1
SCHEMBL29046102 0.86 MAPK1 (0.38) MAPK1ATMPOLBKDM4EL3MBTL1
SCHEMBL31003355 0.83 MAPK1 (0.41) MAPK1ATMPOLBKDM4EL3MBTL1
SCHEMBL3372466 0.83 MAPK1 (0.41) MAPK1ATMPOLBKDM4EL3MBTL1
SCHEMBL25933699 0.81 OPRK1 (0.41) MAPK1ATMPOLBPDGFRBKDR
SCHEMBL30413012 0.79 KDM1A (0.38) MAPK1ATMPOLBKDM4EL3MBTL1
SCHEMBL24215555 0.79 KDM1A (0.38) MAPK1ATMPOLBKDM4EL3MBTL1
SCHEMBL24214090 0.78 CYP11B1 (0.41) MAPK1ATMPOLBKDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250106-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250106-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 MAPK1 1593/4885ATM 110/4885MGLL 1005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.